Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ATP4A | P20648 | 1/20 | 0.38 |
| ▸ | ATP4B | P51164 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20544749 | 0.78 | MAPT (0.44) | KDM4EADORA2AMAPT | |
| SCHEMBL20544973 | 0.76 | KEAP1 (0.37) | KEAP1NFE2L2HTR1AADRA1DADRA1A | |
| SCHEMBL31726732 | 0.75 | KEAP1 (0.47) | KEAP1NFE2L2HTR1AADRA1DADRA1A | |
| SCHEMBL20544577 | 0.72 | GAA (0.45) | KEAP1NFE2L2HTR1AADRA1DADRA1A | |
| SCHEMBL31725398 | 0.71 | MEN1 (0.49) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL16964453 | 0.69 | HTR1A (0.60) | TOP2ATOP2BHTR1AADRA1DADRA1A | |
| SCHEMBL11065307 | 0.67 | ATP4A (0.51) | HTR1AADRA1DADRA1AADRA1BATP4A | |
| SCHEMBL11195641 | 0.67 | NQO2 (0.50) | KEAP1NFE2L2HTR1AADRA1DADRA1A | |
| SCHEMBL13486908 | 0.66 | MEN1 (0.49) | KDM4EALDH1A1HPGDMEN1MAPT | |
| SCHEMBL19618108 | 0.66 | MCHR1 (0.51) | TOP2ATOP2BKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831942-B | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3998269-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3615533-B1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| CN-110831942-A | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885TOP2A 754/4885 |
| US-20200270252-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885TOP2A 754/4885 |
| US-20180312507-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885TOP2A 754/4885 |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885TOP2A 754/4885 |
| US-10975078-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | KEAP1 2630/4885NFE2L2 2508/4885TOP2A 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.